---
title: "Guangzhou Innogen Wins Approval to Start Trials on Pet Diabetes Drug Efsubaglutide Alfa"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274887236.md"
description: "Guangzhou Innogen Pharmaceutical Group has received approval from China's Ministry of Agriculture and Rural Affairs to start Phase I clinical trials for its pet diabetes drug, Efsubaglutide Alfa, expected to begin in Q1 2026. The company sees a significant market potential in diabetic medicines for pets, supported by positive pre-clinical data. However, successful commercialization remains uncertain. The current analyst rating for Guangzhou Innogen's stock (HK:2591) is a Hold, with a price target of HK$30.00 and a market cap of HK$13.17B."
datetime: "2026-02-04T14:42:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274887236.md)
  - [en](https://longbridge.com/en/news/274887236.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274887236.md)
---

# Guangzhou Innogen Wins Approval to Start Trials on Pet Diabetes Drug Efsubaglutide Alfa

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has issued an announcement.

Guangzhou Innogen Pharmaceutical Group has announced that China’s Ministry of Agriculture and Rural Affairs has officially accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa, a core product being developed for the treatment of diabetes in companion animals, with Phase I clinical trials expected to begin in the first quarter of 2026. The company views diabetic medicines for pets as a high-potential market aligned with its long-term strategy, noting that positive pre-clinical efficacy and safety data support further development and potential registration, which could lay the groundwork for a broader expansion into companion animal drug products, although successful commercialization is not guaranteed.

The most recent analyst rating on (HK:2591) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H stock, see the HK:2591 Stock Forecast page.

**More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H**

Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company whose business includes the research and development of innovative drug products, and it is now extending its focus into the companion animal health market, particularly targeting treatments for pet diabetes.

**Average Trading Volume:** 1,030,530

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$13.17B

For an in-depth examination of 2591 stock, go to TipRanks’ Overview page.

### Related Stocks

- [02591.HK](https://longbridge.com/en/quote/02591.HK.md)

## Related News & Research

- [CICC Starts Guangzhou Innogen Pharmaceutical Group at Outperform with HK$28.10 Price Target](https://longbridge.com/en/news/282318531.md)
- [Tractive’s new dog and cat trackers provide more health insights for your pets](https://longbridge.com/en/news/282046276.md)
- [Animal Rescue Corps rescues eight neglected pit bulls with aid from local law enforcement](https://longbridge.com/en/news/282348136.md)
- [Hong Kong animal groups urge HKTVmall boycott over life science experiments](https://longbridge.com/en/news/282337543.md)
- [09:03 ETMeet Wellness Pet's Newest Pack Member: Alex Toussaint](https://longbridge.com/en/news/281887237.md)